FDA Pilot Program Allows Unapproved AI Medical Devices to Reach Patients

5:04 AM ETDeveloping

Health Desk

In Short: The Food and Drug Administration has launched a pilot program allowing certain generative AI medical devices to be released to patients before full authorization, including products from Cadence and Limbic.

The Food and Drug Administration (FDA) is experimenting with a new approach to regulating medical devices that use generative artificial intelligence (AI) to make healthcare decisions. Through its TEMPO pilot program, the agency is allowing some developers to launch their AI products on the market without full marketing authorization.

Four devices, including those from companies Cadence and Limbic, have been accepted into this pilot program, which aims to increase the availability of technologies for the Medicare ACCESS model, an initiative focused on managing chronic conditions.

This move not only provides early access to innovative AI technologies for patients but also gives the FDA and companies the opportunity to test and refine AI regulation in real-world settings.

The pilot program is seen as a way to balance the need for rapid innovation in AI medical devices with the need for robust safety and efficacy standards.

What's confirmed

What's still developing

Test your knowledge with our new weekday mini crossword As the Food and Drug Administration wrestles with how to regulate medical devices that rely on generative artificial intelligence to make decisions about care,…
AI products from Cadence and Limbic are among four devices recently accepted into the agency’s TEMPO pilot program that will allow digital health companies to release their products without marketing authorization.
The pilot is intended to beef up the number of technologies available for the Medicare ACCESS model, an experiment in paying for technology to help beneficiaries manage chronic conditions.
But it also offers the agency and companies the opportunity to experiment with AI regulation in the real world.
To read the rest of this story subscribe to STAT+.
You may opt out of receiving STAT communications at any time.

Sources

STATlink